Ethambutol/isoniazid/rifampicin: Difference between revisions
CSV import |
CSV import |
||
| Line 42: | Line 42: | ||
{{medicine-stub}} | {{medicine-stub}} | ||
{{No image}} | {{No image}} | ||
__NOINDEX__ | |||
Latest revision as of 11:12, 17 March 2025
Ethambutol/Isoniazid/Rifampicin is a combination medication used in the treatment of tuberculosis. It contains three antibiotics: ethambutol, isoniazid, and rifampicin. This combination is often used in the initial phase of tuberculosis treatment to reduce the development of drug resistance.
Composition[edit]
The medication is composed of three active ingredients:
- Ethambutol: This antibiotic interferes with the formation of the cell wall in the Mycobacterium tuberculosis bacteria, causing them to die.
- Isoniazid: Isoniazid is a first-line antitubercular medication that works by preventing the bacteria from forming mycolic acid, which is necessary for their cell walls.
- Rifampicin: Rifampicin inhibits DNA-dependent RNA polymerase in the bacteria, preventing them from replicating.
Usage[edit]
Ethambutol/Isoniazid/Rifampicin is used in the initial phase of tuberculosis treatment, typically for two months. This is followed by a continuation phase of four to six months with isoniazid and rifampicin alone. The medication is taken orally, usually once a day.
Side Effects[edit]
Like all medications, Ethambutol/Isoniazid/Rifampicin can cause side effects. These may include:
Patients should contact their healthcare provider if they experience any unusual symptoms while taking this medication.
Precautions[edit]
Before starting treatment with Ethambutol/Isoniazid/Rifampicin, patients should inform their healthcare provider if they have any other medical conditions, especially:
See Also[edit]
